A Critical Commentary on "Synthetic α-synuclein fibrils replicate in mice causing MSA-like pathology". Burger et al., Nature 2025; doi: 10.1038/s41586-025-09698-1.

1 A Critical Commentary on “Synthetic α-synuclein fibrils replicate in mice causing MSA-like pathology”. Burger et al., Nature 2025; doi: 10.1038/s41586025-09698-1. Mengxi Zhu and Shu-Feng Zhou* College of Chemical Engineering, Huaqiao University, Xiamen, China *Correspondence: [email protected] Introduction Burger et al.1 (2025) report that synthetic α-synuclein fibrils (Syn-Fibs) are capable of replicating in vivo and producing multiple-system-atrophy (MSA)-like pathology in mice. The article aims to resolve a long-standing debate about whether misfolded α-synuclein alone is sufficient to seed and propagate MSA-type inclusion pathology characteristic of glial cytoplasmic inclusions (GCIs). While the study represents an ambitious and technically sophisticated effort, it presents several conceptual inconsistencies, methodological blind spots, quantification weaknesses, and interpretation over-reach. Below, we provide a systematic, figure-by-figure critique—including Extended Data Figures and Supplementary Figures—highlighting issues of experimental design, statistical analysis, image integrity, model validity, and claims exceeding evidence. Main Commentary 1. Introduction and Conceptual Framing The authors propose that synthetic α-synuclein fibrils, assembled in vitro, can selfpropagate in vivo and replicate an MSA-like phenotype—arguing that this demonstrates the "infectious prion-like nature" of Syn-Fibs. This framing has three weaknesses: 1. Assumption of purity – Synthetic α-synuclein fibrils generated in vitro often contain structural polymorphs. The authors do not demonstrate that the fibril batches used across experiments are homogeneous or stable across preparations. 2 2. Overextension of “replication” terminology – Fibril elongation or seeding does not inherently constitute “replication” in the biological or prion sense; the conceptual leap is unjustified without biochemical kinetic evidence. 3. Absence of longitudinal, in vivo biochemical characterization – Without serial biochemical tracing of fibril structure in mouse brains, the authors cannot convincingly argue that the fibrils maintain their MSA-like conformational state. These foundational issues permeate the entire manuscript and affect the interpretation of all figures. Figure-by-Figure Critique Figure 1 – Structural and biochemical characterization of synthetic α-synuclein fibrils Overall assessment: The authors claim that the fibrils adopted a “distinct MSA-like conformation,” but the structural analyses presented are insufficient to substantiate that claim. Major criticisms: 1.1 Cryo-EM resolution inconsistencies • The reported map resolution (~3.2–3.6 Å) is not adequate to confidently assign sidechain rotamers distinguishing MSA-polymorphs from PD-polymorphs. • Sharpening and filtering parameters are poorly described. • The figure panels lack local resolution heatmaps, preventing readers from evaluating heterogeneous regions. 1.2 Polymorph heterogeneity not addressed The study does not provide: • 2D class distributions, • classification of polymorph sub-populations, • fibril twisting periodicity variability. This omission undermines the claim that the fibrils represent a single defined structural species. 1.3 Missing biochemical characterization The authors do not provide: • protease resistance profiles, 3 • sedimentation assays, • conformational stability curves. These are standard prion-replication metrics. Without them, the structural assertions are weak. 1.4 Lack of comparison to bona fide human MSA fibrils Panels show superficial similarity, but: • alignment metrics, • RMSD values, • cross-sections, • backbone overlays are missing. The figure thus overstates similarities. Figure 2 – In vivo inoculation and distribution of pathology Overall assessment: The figure claims widespread propagation of fibril seeds and resulting pathology, but both the experimental design and quantification are insufficiently rigorous. 2.1 Injection parameters poorly controlled Critical omissions: • Exact coordinates for all injection replicates. • Needle gauge, infusion rate, dwell time. • Batch variability of fibrils. This prevents reproducibility. 2.2 Pathology quantification lacks stereology The authors use: • % area coverage, • relative fluorescence units, • arbitrary thresholds. No unbiased stereology (e.g., optical fractionator), which is the gold standard for neurodegeneration quantification. 2.3 Missing controls The crucial control groups are either absent or underdeveloped: 4 • Heat-inactivated fibrils • Monomeric α-synuclein • Scrambled fibrils • PBS with identical injection trauma A figure that purports propagation but lacks critical negative controls is not convincing. 2.4 Ambiguous immunostaining Antibodies used (pS129 α-synuclein) are notorious for nonspecific binding when tissue fixation is suboptimal. The authors do not report: • fixation duration, • antigen retrieval method, • background subtraction procedures. Thus the pathology distribution is difficult to interpret. Figure 3 – MSA-like glial cytoplasmic inclusion (GCI) formation This is the key figure supporting the central claim. It is also the weakest. 3.1 Failure to show ultrastructural GCIs While the authors display immunostained inclusions: • No electron microscopy evidence is provided for true GCI morphology. • GCIs have distinct ultrastructural signatures (compact, ring-like stacking); none are shown. Thus, the claim “MSA-like GCI formation” is not supported. 3.2 Poor differentiation between neuronal and glial inclusions The authors rely on markers: • Olig2, • GFAP. However: • Olig2 labels progenitors, not exclusively mature oligodendrocytes. • GFAP is upregulated by stress and is not specific for inclusion-bearing glia. Co-localization is insufficient without: • high-resolution z-stacks, • cell-type-restricted reporters. 5 3.3 Missing quantification of glial-only vs neuronal-only inclusion frequencies The authors claim glial predilection, but: • numeric comparison is missing, • relative burden is not reported, • sample sizes are small (n = 3 per group). 3.4 Possible image over-contrast or mis-adjustment Some panels display: • blown-out highlights, • halos around inclusions, • possible over-sharpening. This risks artificial enhancement of pathology. Figure 4 – Behavioral phenotypes The claim: Syn-Fibs induce motor and autonomic deficits resembling MSA. 4.1 Choice of behavioral tests is insufficient MSA involves: • autonomic failure, • parkinsonism, • cerebellar ataxia. The authors only test: • rotarod, • pole test, • open field. These reflect general motor deficits, not MSA-specific impairments. Missing: • autonomic assays (blood pressure variability), • cerebellar tests, • respiratory patterning, • urodynamic assessments. Thus, the behavioral evidence is nonspecific. 6 4.2 Sample sizes too small n = 6–7 per group is inappropriate for: • rotarod performance (high variability), • complex motor tests. Statistical power is not evaluated. 4.3 Blinding procedures unclear No statement confirming: • behavioral scoring blinding, • randomization of treatment allocations. 4.4 Missing longitudinal trajectories Acute vs chronic deficits are indistinguishable from this figure. Figure 5 – Biochemical propagation and strain labeling This figure attempts to show that fibrils extracted from mouse brains retain their "strain identity". 5.1 Proteinase K digestion insufficient Prion strain identification via PK resistance requires: • multi-concentration digests, • time-course curves, • mass spectrometry of cleavage fragments. The authors provide only: • single time point, • single concentration, • low-resolution Western blots. This does not establish strain retention. 5.2 Amplification assays lack rigor The authors use PMCA-like assays, but: • cross-contamination is a major risk and is not addressed. • negative controls are faintly shown or missing. 7 5.3 Missing quantitative kinetics Propagation curves lack: • lag phase estimation, • growth rate calculation, • endpoint saturation behaviors. This is required to define “replication”. Figure 6 – Neurodegeneration and oligodendrocyte dysfunction This figure claims that Syn-Fibs induce selective oligodendrocyte vulnerability resembling MSA. 6.1 Cell counting not stereologically validated Counts are made using: • thresholded segmentation, • region of interest (ROI) selection. ROIs appear inconsistently placed across animals. 6.2 Myelin staining inconsistent MBP staining brightness: • drastically differs across panels, • appears possibly adjusted post-acquisition, • lacks internal fluorescence standards. 6.3 Failure to demonstrate true demyelination True demyelination requires: • g-ratio analysis via EM, • paranodal disruption (Caspr staining), • axonal swelling measures. None are shown. 6.4 Possible circular reasoning The authors assume α-synuclein inclusions → oligodendrocyte dysfunction. But the images merely show colocalization, not causation. 8 Figure 7 – Therapeutic intervention experiments This figure tests anti-α-synuclein antibodies or inhibitors. 7.1 Short treatment window Therapy is initiated very early after inoculation—before pathology seeds stabilize. Thus, the study tests prevention, not treatment, though the authors claim therapeutic efficacy. 7.2 Dosing unclear The figure does not report: • mg/kg, • dosing schedule, • brain penetration estimates. 7.3 Pathology reduction metrics unreliable Figures rely on: • threshold-based quantification, • non-linear fluorescent signals, • potentially biased ROI sampling. 7.4 Overinterpretation From minimal reductions in staining intensity, the authors conclude “rescue of pathology,” which is an exaggeration. Extended Data Figure Critiques The Extended Data Figures contain several methodological inconsistencies. Extended Data Figure 1 – Additional fibril structural analyses • No reproducibility across multiple batches. • No comparison to wild-type vs mutant α-synuclein fibrils. • Insufficient reporting of alignment parameters in cryo-EM reconstructions. Extended Data Figure 2 – Additional pathology maps • Heatmaps are low resolution and possibly smoothed excessively. • Color scales differ between samples, preventing comparison. • Missing raw counts and slice numbers. 9 Extended Data Figure 3 – Antibody validation • No dot-blot or peptide competition tests. • Antibody specificity for fibrillar vs monomeric α-syn not demonstrated. Extended Data Figure 4 – Cell-type resolution • Single-plane images only; no 3D reconstructions. • Cannot distinguish engulfed fibrils (by microglia) vs true intracellular inclusions. Extended Data Figure 5 – Fibril preparation QC • Dynamic light scattering results appear inconsistent with fibril lengths observed under EM. • Missing endotoxin analysis—endotoxin contamination can generate glial phenotypes resembling MSA. Extended Data Figure 6 – Behavioral raw scores • Large variance indicates insufficient statistical power. • No sex-specific analysis. • Control mice underperform compared to standard colony averages, raising general welfare concerns. Extended Data Figures 7–10 – Blot quantification and replication experiments • Densitometry lacks linear range validation. • Blots appear overexposed. • Some lanes show artifacts resembling horizontal smearing—possible transfer issues. Supplementary Figure Critiques Supplementary Figure 1 – Full cryo-EM processing pipeline • Missing 2D/3D classification flow charts. • Particle number reduction from initial picking to final map is unusually large (~85% loss), suggesting instability of fibrils. Supplementary Figure 2 – Raw behavioral videos (frames) • Selected frames do not illustrate deficits clearly. • No blinded scoring shown. Supplementary Figure 3 – PMCA assay raw traces • Baseline drift and noise are not corrected.